Sleigh K M, Danforth D G, Hall R T, Fleming J A, Stiver H G
Division of Infectious Disease, Department of Medicine, University of British Columbia, Vancouver, British Columbia.
Can J Infect Dis. 2000 Sep;11(5):267-73. doi: 10.1155/2000/602862.
To determine whether influenza immunization is associated with early side effects, a deleterious impact on the illness course and depressed antibody response in patients with chronic fatigue syndrome (CFS).
Prospective, randomized, double-blind, placebo controlled trial. CFS patients and healthy volunteers filled out a questionnaire on immunization side effects and had hemagglutination-inhibiting (HI) antibody titres measured pre- and three weeks after immunization. CFS patients completed symptom and function questionnaires before and during the six-week, postimmunization period.
Ambulatory care.
Convenience sample of 40 CFS patients fulfilling the Centers for Disease Control and Prevention criteria and 21 demographically matched healthy volunteers.
CFS patients were randomly selected to receive commercially available whole virus influenza vaccine (n=19) or an injection of saline placebo (n=21). Healthy volunteers received vaccine only.
As a group, immunized CFS patients had lower geometric mean HI antibody rises than healthy volunteers (P<0.001). However, there was no difference in the rates of fourfold titre rises, and immunization did achieve a probably protective titre (1:32 or greater) in most CFS patients. No difference could be detected between immunized and placebo CFS patients in immunization side effects, although CFS patients as a group reported four times as many side effects as healthy volunteers. Further, in the six weeks following immunization, placebo and immunized CFS patients did not demonstrate any differences in terms of functioning, symptom severity and sleep disturbance.
In patients with CFS, influenza immunization is safe, not associated with any excess early reactions, and stimulates an immunizing response comparable with that of healthy volunteers.
确定流感疫苗接种是否与慢性疲劳综合征(CFS)患者的早期副作用、对病程的有害影响以及抗体反应降低有关。
前瞻性、随机、双盲、安慰剂对照试验。CFS患者和健康志愿者填写了关于疫苗接种副作用的问卷,并在接种前和接种后三周测量了血凝抑制(HI)抗体滴度。CFS患者在接种后六周内完成了症状和功能问卷。
门诊护理。
40名符合疾病控制与预防中心标准的CFS患者和21名人口统计学匹配的健康志愿者的便利样本。
随机选择CFS患者接受市售全病毒流感疫苗(n = 19)或注射生理盐水安慰剂(n = 21)。健康志愿者仅接受疫苗。
作为一个群体,接种疫苗的CFS患者的几何平均HI抗体升高低于健康志愿者(P<0.001)。然而,四倍滴度升高的发生率没有差异,并且接种疫苗在大多数CFS患者中确实达到了可能具有保护作用的滴度(1:32或更高)。尽管CFS患者作为一个群体报告的副作用是健康志愿者的四倍,但在接种疫苗的CFS患者和安慰剂组患者之间未检测到接种副作用的差异。此外,在接种后的六周内,安慰剂组和接种疫苗的CFS患者在功能、症状严重程度和睡眠障碍方面没有表现出任何差异。
在CFS患者中,流感疫苗接种是安全的,与任何额外的早期反应无关,并能刺激与健康志愿者相当的免疫反应。